Cost-effectiveness of a stepped care intervention to prevent depression and anxiety in late life: randomised trial
暂无分享,去创建一个
F. Smit | A. Beekman | H. van Marwijk | H. V. van Hout | P. van Oppen | H. E. van der Horst | Petronella J van't Veer-Tazelaar
[1] P. Cuijpers,et al. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. , 2009, Archives of general psychiatry.
[2] Filip Smit,et al. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. , 2008, The American journal of psychiatry.
[3] P. Cuijpers,et al. Costs of nine common mental disorders: implications for curative and preventive psychiatry. , 2006, The journal of mental health policy and economics.
[4] P. Cuijpers,et al. Cost-effectiveness of preventing depression in primary care patients: Randomised trial , 2007 .
[5] P. Cuijpers,et al. Minimal-contact psychotherapy for sub-threshold depression in primary care , 2004, British Journal of Psychiatry.
[6] A. Beekman,et al. Patients' preferences in the treatment of depressive disorder in primary care. , 2004, General hospital psychiatry.
[7] S. Byford,et al. Acceptable mental health care? A new decision-making tool for cost-effectiveness analysis - Mental Health Research Review 9 , 2003 .
[8] A. Beekman,et al. The impact of depression on the well‐being, disability and use of services in older adults: a longitudinal perspective , 2002, Acta psychiatrica Scandinavica.
[9] W. Katon,et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. , 2001, The American journal of psychiatry.
[10] A. V. van Balkom,et al. Consequences of anxiety in older persons: its effect on disability, well-being and use of health services , 1999, Psychological Medicine.
[11] N. Pelosi. Reducing risks of mental disorders. , 1996, American Psychologist.
[12] George W. Torrance,et al. Canadian Guidelines for Economic Evaluation of Pharmaceuticals , 1996, PharmacoEconomics.
[13] P. Langley. The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals , 1996, PharmacoEconomics.
[14] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[15] L. Roijen,et al. Manual Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness , 2002 .
[16] M C Weinstein,et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.
[17] A. Detsky,et al. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. , 1996, PharmacoEconomics.